A5019021403- Liver Disease Diagnosis and Treatment
- Diet, Metabolism, and Disease
- Liver Disease and Transplantation
- Pancreatitis Pathology and Treatment
- Alcohol Consumption and Health Effects
- Diet and metabolism studies
- Cardiovascular Disease and Adiposity
- Hepatitis C virus research
- Metabolomics and Mass Spectrometry Studies
- Hepatitis B Virus Studies
- Lipoproteins and Cardiovascular Health
- Analytical Chemistry and Chromatography
- Mass Spectrometry Techniques and Applications
- Hepatocellular Carcinoma Treatment and Prognosis
- Peptidase Inhibition and Analysis
- Diamond and Carbon-based Materials Research
- Cardiac tumors and thrombi
- Peroxisome Proliferator-Activated Receptors
- Gut microbiota and health
- Clostridium difficile and Clostridium perfringens research
- Metabolism and Genetic Disorders
- Systemic Sclerosis and Related Diseases
- Folate and B Vitamins Research
- Liver Diseases and Immunity
- Cancer, Lipids, and Metabolism
The First Affiliated Hospital, Sun Yat-sen University
2019-2025
Sun Yat-sen University
2019-2025
Weatherford College
2022
University Gastroenterology
2022
Abstract Background and Aim The introduction of the latest nomenclature, metabolic associated steatotic liver disease (MASLD), proposed by multi‐society without Asian society consensus statement, aims to redefine diagnostic criteria for fatty (MAFLD). However, its effect on epidemiology in Asia remains unclear. Method We conducted a population‐based cross‐sectional survey using multistage stratified random sampling participants from Guangzhou, representative area China (ChiCTR2000033376)....
The liver effect of orlistat as a weight control treatment in patients with nonalcoholic fatty disease (NAFLD) obesity remains undetermined. This study quantified fat improvement by Chinese cohort NAFLD accompanied obesity, diagnosed lower body mass index threshold than that for White patients.We conducted parallel-group, open-label, 24-week, randomized clinical trial registered at the Clinical Trial Registry (ChiCTR-IPR-17012258). Obese participants were 1:1.5 to intervention group or...
Losing weight by lifestyle interventions is the first-line treatment for metabolic-associated fatty liver disease (MAFLD) but limited low compliance.This study aimed to compare effects of orlistat or an experimental high-protein/lower-carbohydrate diet with a control in Asian patients obesity and MAFLD.A total 118 MAFLD confirmed MRI-based proton density fat fraction Dixon sequence were enrolled allocated group, group 24 wk. The primary endpoint was relative change content (LFC) assessed...
Background: Previous studies have verified that metabolic dysfunction-associated steatotic liver disease (MASLD) confered higher risk of coronary atherosclerosis development. However, whether MASLD influence prognosis after drug-eluting stent (DES) implantation treatment remain not known. Methods: In this retrospective observational study, 301 included cardiovascular (CVD) patients who underwent re-coronary angiography the first successful DES-based percutaneous intervention. All received...
The recent FDA-approval of resmetirom for treating metabolic dysfunction-associated steatohepatitis (MASH) in patients necessitates patient selection significant fibrosis or higher (≥F2). No existing vibration-controlled transient elastography (VCTE) algorithm targets ≥F2. ALADDIN study addressed this gap by introducing a machine-learning-based web calculator that estimates the likelihood using routine laboratory parameters with and without VCTE. Our included Training set 827 patients,...
Background: The clinical burden and natural history of non-alcoholic fatty liver disease (NAFLD) vary globally. We aimed to investigate NAFLD-related mortality profiles in hospitalized patients southern China. Methods: A multicenter retrospective investigation with a 10-year study period (2009–2018) analyzed 10,071 deaths during hospitalization (NAFLD: 2,015; other diseases: 1,140; without 6,916) was performed using multiple cause death analysis. Medical histories biochemistry imaging...
Nonobese metabolic dysfunction-associated fatty liver disease (MAFLD) is paradoxically associated with improved and pathological features at diagnosis but similar cardiovascular diseases (CVD) prognosis to obese MAFLD. We aimed utilize the metabolomics identify potential metabolite profiles accounting for this phenomenon.This prospective multicenter cross-sectional study was conducted in China enrolling derivation validation cohorts. Liquid chromatography coupled mass spectrometry gas...
Insulin resistance (IR) related metabolic disorders are associated with a worse prognosis of chronic hepatitis B virus (CHB) infection or nonalcoholic fatty liver disease (NAFLD). However, the relationships among CHB, steatosis, IR and factors remain controversial. The study aims to evaluate impact insulin severity on profiles in patients NAFLD coincidence two.We conducted cross-sectional between January 2011 December 2018 that included 2768 consecutive Chinese subjects (healthy controls:...
Purpose: Effective treatment of dyslipidemia with lipid-lowering agents is pivotal in the management metabolic-associated fatty liver disease (MAFLD) for preventing cardiovascular complications. We explored associations between improvements injuries indicated by changes transaminases and a reduction lipid levels MAFLD patients elevated during therapies. Methods: This prospective, cohort study enrolled consecutive hyperlipidemia transaminases. Patients were divided into group receiving an...
Abstract Background The normalization of liver biochemical parameters usually reflects the histological response to treatment for nonalcoholic fatty disease (NAFLD). Researchers have not clearly determined whether different enzymes exhibit various metabolic changes during follow-up period in patients with NAFLD. Methods We performed a retrospective analysis NAFLD who were receiving therapy from January 2011 December 2019. Metabolism indexes, including glucose levels, lipid profiles, uric...
This study seeks to evaluate the effects of a reversal sedentary lifestyles on improvement metabolic profiles in patients with NAFLD. The PubMed, Cochrane Library, Web Science, and CNKI databases were searched up May 15, 2021. Ten randomized controlled trials changes lifestyle NAFLD included analysis. Data from self-controlled case arms investigating alterations extracted, effect size was reported as MD 95% CI. A total 455 participants 10 studies met selection criteria. results showed that...
Hepatic fibrosis reduces the serum level of lipoprotein (a) (Lp(a)) and may affect its accuracy in cardiovascular disease prediction metabolic-associated fatty liver (MAFLD). We aimed to estimate association between Lp(a) levels risk carotid atherosclerosis MAFLD patients with advanced fibrosis.This was a cross-sectional study enrolling 4,348 consecutive individuals (1,346 3,002 non-MAFLD patients) who were admitted First Affiliated Hospital, Sun Yat-sen University, underwent abdominal...
Excessive delivery of free fatty acids (FFAs) to the liver promotes steatosis and insulin resistance (IR), with IR defined as reduced glucose uptake, glycogen synthesis anti-lipolysis stimulated by normal levels. Whether associations between FFAs diabetes development differ patients without nonalcoholic disease (NAFLD) remains unclear.Consecutive subjects (2,220 NAFLD 1,790 non-NAFLD according ultrasound imaging) were enrolled from First Affiliated Hospital Sun Yat-sen University 2009 2019....
Background Progressive overloads of intrahepatic triglycerides are related to metabolic dysregulation multiple lipid and lipoprotein profiles, but whether similar dose effects found in each subtype associated fatty liver disease (MAFLD) remains unclear. We aimed characterize the profiles with fat content (LFC) MAFLD patients who were overweight, lean/normal weight, or had diabetes. Methods conducted a cross-sectional study enrolling 1,182 consecutive participants (144 non-MAFLD 1,038 MAFLD)...
Two-dimensional shear wave elastography (2D-SWE) can be used to accurately assess significant liver fibrosis in chronic hepatitis B (CHB). However, whether those with decompensated cirrhosis could benefit from surveillance 2D-SWE remains unclear. We aimed evaluate the association between dynamic changes measurements and prognosis of CHB-related cirrhosis.We prospectively enrolled 149 consecutive treatment-naive CHB patients a clinical trial (registration number: ChiCTR-DCD-15006000) February...
Background and AimsThe redefinition of metabolic-associated fatty liver disease (MAFLD) from nonalcoholic (NAFLD) has caused a revolution in clinical practice, the characteristics patients with steatosis but not MAFLD remain unclear. The aims were to compare diagnosis rate NAFLD using different methods explore features non-MAFLD–NAFLD MAFLD–non-NAFLD.
Whether the associations between serum vitamin D (VitD) and metabolic-associated fatty liver disease (MAFLD) vary with chronic hepatitis B (CHB) infection has not been well established. This study aims to investigate relationships VitD metabolism, fat content (LFC) fibrosis among MAFLD patients without CHB. Consecutive subjects (healthy controls: 360, CHB: 684, MAFLD: 521, CHB 206) were prospectively enrolled January 2015 December 2021. Anthropometric, laboratory, imaging, histological...
Propranolol (PROP) is a nonselective β-adrenergic receptor antagonist used to treat hypertension and cardiac arrhythmias. Oral administration of PROP has recently emerged as new treatment modality for hemangiomas. However, the side effects at cellular level have not been adequately described.The present study investigates highlights mechanisms coupling drugs cyclosporin-A (CyA) on cell proliferation occurrence apoptosis. It also relays antioxidant effect human umbilical vein endothelial...
Background: Abnormal phospholipid metabolism is linked to metabolic dysfunction–associated steatotic liver disease (MASLD) development and progression. We aimed clarify whether genetic variants of modify these relationships. Methods: This case-control study consecutively recruited 600 patients who underwent MRI-based proton density fat fraction examination (240 participants with serum metabonomics analysis, 128 biopsy-proven cases) as 3 groups: healthy control, nonobese MASLD, obese (n = 200...
The application of desorption electrospray ionization mass spectrometry (DESI-MS) and dried blood spot (DBS) sampling has been successfully implemented several times. However, the difficulty combining DBS with DESI-MS is still carrier material used for samples. In this study, a new, easily obtained, cost-effective substrate plasma (DPS) analysis its in phospholipidomics studies was described. First, effects materials, including cellulose-based materials (31 ET paper filter paper)...